Jennifer Woyach


Jennifer Woyach

Unit / Department / Division
Department of Internal Medicine
Division of Hematology
Email Address
Phone Number


  • 2005, MD, Cum laude, Ohio State University College of Medicine, Medicine
  • 2001, BS, Magna cum Laude, University of Notre Dame, Preprofessional Studies and Psychology
  • Basic Life Support, American Heart Association
  • Board Certified, American Board of Internal Medicine (ABIM)
  • Board Certified, American Board of Internal Medicine (ABIM)
  • Board Certified, American Board of Internal Medicine (ABIM)
  • Advanced Cardiac Life Support, American Heart Association


  • American Society of Clinical Investigation Young Physician-Scientist Award, 2015
  • Grever Distinguished Professor Lectureship, 2014
  • Early Career Achievement Award, 2014
  • James V. Warren Internal Medicine Fellow research Award, 2012


  • Biomarkers of Bruton Tyrosine Kinase Inhibitor Resistance (2014, October). 62/059,501.
  • Phospholipase C Gamma 2 and Resistance Associated Mutation (2014, March). 61/968,315.


  • Rogers, K.A.; Huang, Y.; Ruppert, A.S.; Awan, F.T. et al. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia BLOOD. 2018 Oct; 132(15):1568-1572.
  • Bottoni, A.; Rizzotto, L.; Lai, T-H.; Liu, C. et al. Targeting BTK through microRNA in chronic lymphocytic leukemia Blood. 2016 Dec; 128(26):3101-3112.
  • Rogers, K.A.; Woyach, J.A. Secondary autoimmune cytopenias in chronic lymphocytic leukemia. Seminars in oncology. 2016 Apr; 43(2):300-310.
  • Fraietta,Joseph,A; Beckwith,Kyle,A; Patel,Prachi,R; Ruella,Marco; Zheng,Zhaohui; Barrett,David,M; Lacey,Simon,F; Melenhorst,Jan,Joseph; McGettigan,Shannon,E; Cook,Danielle,R; Zhang,Changfeng; Xu,Jun; Do,Priscilla; Hulitt,Jessica; Kudchodkar,Sagar,B; Cogdill,Alexandria,P; Gill,Saar; Porter,David,L; Woyach,Jennifer,A; Long,Meixiao; Johnson,Amy,J; Maddocks,Kami; Muthusamy,Natarajan; Levine,Bruce,L; June,Carl,H; Byrd,John,C; Maus,Marcela,V Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016 Mar; 127(9):1117-1127.
  • Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia LEUKEMIA. 2016 Feb; 30(2):346-350.
  • Wall, S.; Woyach, J.A. Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. Clinics in geriatric medicine. 2016 Feb; 32(1):175-189.
  • Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, Chaves J, Wierda WG, Awan FT, Brown JR, Hillmen P, Stephens DM, Ghia P, Barrientos JC, Pagel JM, Woyach J, Johnson D, Huang J, Wang X, Kaptein A, Lannutti BJ, Covey T, Fardis M, McGreivy J, Hamdy A, Rothbaum W, Izumi R, Diacovo TG, Johnson AJ, Furman RJ Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia NEW ENGLAND JOURNAL OF MEDICINE. 2016 Jan; 374(4):323-332.
  • Woyach, J.A. Patterns of resistance to B cell-receptor pathway antagonists in chronic lymphocytic leukemia and strategies for management American Society of Hematology Education Program Book. 2015 Dec; 2015(1):355-360.
  • Hing,Zachary,A; Mantel,Rose; Beckwith,Kyle,A; Guinn,Daphne; Williams,Erich; Smith,Lisa,L; Williams,Katie; Johnson,Amy,J; Lehman,Amy,M; Byrd,John,C; Woyach,Jennifer,A; Lapalombella,Rosa Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia BLOOD. 2015 May; 125(20):3128-3132.
  • Guinn,D; Ruppert,A,S; Maddocks,K; Jaglowski,S; Gordon,A; Lin,T,S; Larson,R; Marcucci,G; Hertlein,E; Woyach,J; Johnson,A,J; Byrd,J,C miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib LEUKEMIA. 2015 May; 29(5):1210-1213.
  • Maddocks KJ, Ruppert A, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA Etiology of Ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia JAMA ONCOLOGY. 2015 Jan; 1 80-87.
  • Liu TM, Ling Y, Woyach JA, Beckwith K, Yeh YY, Hertlein E, Zhang X, Lehman A, Awan F, Jones JA, Andritsos LA, Maddocks K MacMurray J, Salunke SB, Chen CS, Phelps MA, Byrd JC, Johnson AJ OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. BLOOD. 2015 Jan; 125(2):284-295.
  • Dong S, Guinn D, Dubovsky JA, Zhong Y, Lehman A, Kutok J, Woyach JA, Byrd JC, Johnson AJ IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells BLOOD. 2014 Dec; 124(24):3583-3586.
  • Woyach JA, Awan F, Flinn IW, Berdeja JG, Wiley E, Mansoor S, Huang Y, Lozanski G, Foster PA, Byrd JC A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL BLOOD. 2014 Dec; 124(24):3553-3560.
  • Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician JOURNAL OF CLINICAL ONCOLOGY. 2014 Sep; 32(27):3039-3047.
  • El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FT, Jones JJ, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL BLOOD. 2014 Aug; 124(9):1481-1491.
  • Stephens DM, Ruppert AS, Jones JJ, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy R, Heerema NA, Byrd JC Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center LEUKEMIA. 2014 Jun; 28(6):1365-1368.
  • Woyach JA, Furman R, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li HH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz SA, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Bugg JC, Chang BY, Johnson AJ, Byrd JC Resistance mechanisms for the bruton's tyrosine kinase inhibitor Ibrutinib NEW ENGLAND JOURNAL OF MEDICINE. 2014 Jun; 370(24):2286-2294.
  • Woyach JA, Smucker K, Smith Lisa, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones JA, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC Prolonged lymphocytosis during Ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy BLOOD. 2014 Mar; 123(12):1810-1817.
  • Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith L, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DC, Byrd JC, Johnson AJ Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL) BLOOD. 2014 Feb; 123(8):1207-1213.
  • Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong J, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith, LM, Smucker KA, Flynn JM, Jones,Jeffrey A, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes BLOOD. 2013 Oct; 122(15):2539-2549.
  • Gupta VS, Hertlein E, Lu Y, Sass EJ, Lapalombella R, Chen TL, Davis ME, Woyach JA, Lehman A, Jarjoura D, Byrd JC, Lucas DM The proteasome inhibitor Carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-kappa b response in chronic lymphocytic leukemia cells CLINICAL CANCER RESEARCH. 2013 May; 19(9):2406-2419.
  • Woyach JA, Johnson AJ, Byrd JC The B-cell receptor signaling pathway as a therapeutic target in CLL BLOOD. 2012 Aug; 120(6):1175-1184.
  • Woyach JA, Lozanski G, Ruppert AS, Lozanski A, Blum KA, Jones JA, Flynn JM, Johnson AJ, Grever MR, Heerema NA, Byrd JC Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with Flavopiridol: impact of genetic features LEUKEMIA. 2012 Jun; 26(6):1442-1444.
  • Woyach,Jennifer,A; Byrd,John,C Chemotherapy: New FluCam combination therapy has familiar limitations. Nature reviews. Clinical oncology. 2012 Jan; 9(1):14-15.
  • Blum,K,A; Ruppert,A,S; Woyach,J,A; Jones,J,A; Andritsos,L; Flynn,J,M; Rovin,B; Villalona-Calero,M; Ji,J; Phelps,M; Johnson,A,J; Grever,M,R; Byrd,J,C Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol LEUKEMIA. 2011 Sep; 25(9):1444-1451.
  • Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC Chemoimmunotherapy with Fludarabine and Rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow up of CALGB study 9712 JOURNAL OF CLINICAL ONCOLOGY. 2011 Sep; 29(10):1349-1355.
  • Woyach JA, Byrd JC Established Prognostic Markers in Chronic Lymphocytic Leukemia and Use in Clinical Practice ASCO Education Book. 2011 Jun; 2011 242-245.
  • Woyach JA, Lin TS, Lucas MS, Heerema N, Moran ME, Cheney C, Lucas DM, Wei L, Caligiuri MA, Byrd JC A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma LEUKEMIA. 2009 May; 23(5):912-918.
  • Woyach JA, Heerema NA, Zhao J, McFaddin A, Stark A, Lin TS, Andritsos LA, Blum KA, Flynn JM, Jones JA, Byrd JC Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. BRITISH JOURNAL OF HAEMATOLGY. 2009 Mar; 148(5):754-759.
  • Woyach JA, Shah MH New therapeutic advances in the management of progressive thyroid cancer ENDOCRINE RELATED CANCERS. 2009 Jan; 3(16):715-731.
  • Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH Lack of therapeutic effect of the histone deacetylase inhibitor Vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma Journal of Clinical Endocrinology and Metabolism. 2008 Jan; 94(1):164-170.
  • Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones Ja, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ Hypermorphic mutation of phospholipase C, y2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation BLOOD. Dec .
  • Awan FT, Flynn JM, Jones JA, Andritsos LA, Maddocks KJ, Sass EJ, Lucas MS, Chase W, Waymer S, Ling Y, Jiang Y, Phelps MA, Byrd JC, Lucas DM, Woyach JA Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lympyhocytic leukemia and small lymphocytic lymphoma LEUKEMIA LYMPHOMA. Dec .
  • Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC Externally validated predictive clinical model for untreated Del(17p13.1) chronic lymphocytic leukemia patients AMERICAN JOURNAL OF HEMATOLOGY. Dec .
  • Miller CR, Stephens D, Ruppert AS, Racke F, McFaddin A, Breidenbach H, Lin HJ, Waller K, Bannerman T, Jones JA, Woyach JA, Andritsos LA, Maddocks K, Zhao W, Lozanski G, Flynn JM, Grever M, Byrd JC, Heerema NA Jumping translocations, a novel finding in Chronic Lymphocytic Leukaemia BRITISH JOURNAL OF HAEMATOLOGY. Dec .
  • Woyach JA, Johnson AJ Targeted therapies in CLL: mechanisms of resistance and strategies for management BLOOD. Dec .
  • Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke V, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC Safety and activity of BTK inhibitor ibrutinib combined with ofatumamab in chronic lymphocytic leukemia; a phase 1b/2 study. BLOOD. Dec .